Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 2.3.1.291 extracted from

  • Garic, D.; De Sanctis, J.B.; Wojewodka, G.; Houle, D.; Cupri, S.; Abu-Arish, A.; Hanrahan, J.W.; Hajduch, M.; Matouk, E.; Radzioch, D.
    Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme evidence from bench to bedside (2017), J. Mol. Med., 95, 1053-1064 .
    View publication on PubMed

Application

Application Comment Organism
medicine long-chain ceramides are upregulated whereas very long-chain ceramides are downregulated in cell lines, mouse animal model, and patients with cystic fibrosis, compared with their controls. Treatment with fenretinide decreases the levels of long-chain ceramides and increases the levels of very long-chain ceramides Mus musculus
medicine long-chain ceramides are upregulated whereas very long-chain ceramides are downregulated in cell lines, mouse animal model, and patients with cystic fibrosis, compared with their controls. Treatment with fenretinide decreases the levels of long-chain ceramides and increases the levels of very long-chain ceramides Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens Q8N5B7
-
-
Mus musculus Q9D6K9
-
-

Expression

Organism Comment Expression
Mus musculus presence of fenritinide leads to transcriptional downregulation of Cers5 down
Homo sapiens presence of fenritinide leads to transcriptional downregulation of Cers5 down